Mu.Ta.Lig - COST ACTION CA15135

Prof. Wieslawa Agnieszka FOGEL

14 June 2016


General information

Name:   FOGEL
Surname:  Wieslawa Agnieszka
Cell phone number with international prefix: +48 603099849
Country:     Poland
Affiliation:  Medical University of Lodz
Gender: F x□ M
Year of the PhD title:     1979
Personal web page: http://
Previous COST participation: No □ Yes x


List of 10 selected publications within last 5 years

1.Mercedes Unzeta, Gerard Esteban , Irene Bolea,  Wieslawa A. Fogel, Rona R. Ramsay, Moussa B. H. Youdim, Keith F. Tipton and José Marco-Contelles (2016). Multi-Target Directed Donepezil-Like Ligands for Alzheimer’s Disease. Frontiers in Neuroscience | 2 May 2016 | Volume 10 | Article 205.  REVIEW published: 25 May 2016 doi: 10.3389/fnins.2016.00205


2. Fogel WA,  Histamine, in  Encyclopedia of Inflammatory Diseases, pp 1-12,  Michael Parnham (ed)  2015,  DOI 10.1007/978-3-0348-0620-6_42-1,  ISBN: 978-3-0348-0620-6 (Online) Springer Basel


3. Fogel WA, Stasiak A, Maksymowicz M, Kobos J, Unzeta M, Mussur M. (2014) Hepatocyte transplants improve liver function and encephalopathy in portacavally shunted rats. CNS Neurosci Ther. 2014 Jul;20(7):685-91. doi: 10.1111/cns.12265. Epub 2014 Apr 10.
4. Stasiak A, Mussur M, Unzeta M, Samadi A, Marco-Contelles J, Fogel WA. (2014)  Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia. Curr Pharm Des; 20 (2): 161-171.
5. Mondovi B, Fogel WA, Federico R, Calinescu C, Mateescu MA, Rosa AC, Masini E. (2013) Effects of amine oxidases in allergic and histamine-mediated conditions. Recent Pat Inflamm Allergy Drug Discov. 7(1):20-34. Review.


6. Schwelberger, H. G. ,  Ahrens, F., Fogel, WA,  Sanchez-Jimenez, F.  (2013) Histamine Metabolism.  Chapter 3.   In: Histamine H4 Receptor: A Novel Drug Target in Immunoregulation and Inflammation. Holger  Stark (wyd),  London,  Versita
7. Ciepluch K, Ziemba B, Janaszewska A, Appelhans D, Klajnert B, Bryszewska M,  Fogel WA. (2012) Modulation of biogenic amines content by poly(propylene imine) dendrimers in rats. J Physiol Biochem.  68(3):447-54. doi: 10.1007/s13105-012-0158-y. Epub 2012 Feb 28.


8. Stasiak A, Mussur M, Unzeta M, Lazewska D, Kiec-Kononowicz K, Fogel WA.(2011)  The central histamine level in rat model of vascular dementia. J Physiol Pharmacol, 62 (5) 549-58.




Main skills and expertise (up to 5)

1. Biochemistry
2. Pharmacology
3. Animal models
4. Neuroscience
5. Metabolism and function of biogenic amines


Main equipment/facilities available in the participants’ lab (up to 5)

1.        spectrophotometer
2.        spectrofluorometer
3.       Ion trap GCQ



Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

My contribution could be related to the in vivo study of the active compounds designed and synthesized during the course of action by chemists from WG1. The study would be performed  on rats. Compounds may be administered  intragastrally or by injection either  subcutaneous, intraperitoneal or intravenous.  Biological activity assessment may include the analyses of the drug effects on CNS function based on both,  neurotransmitter concentration and the activity of enzymes engaged in neurotransmitter metabolism (decarboxylases, methyltransferases, monoamine oxidases).  Also ex vivo receptor binding study can be performed when appropriate. Some behavioural studies are also possible- for example, the active and passive avoidance to search the cognitive function impairment or the effects of the administered compounds on  feeding behavior (for neurotransmitters histamine and serotonin).



Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 3
WG2: Selection of biological targets and assessment of biological data 1
WG3: Development of chemical databases 4
WG4: Development of Computational methods for multiple ligand design and discovery 4